One important implication of this is the necessity of using strict diagnostic criteria when designing trials for testing drugs. To the practitioner it is equally important (in a clinical situation) to use the same strict criteria when looking for the drug of choice and its optimal concentration in serum.
Varying responsiveness of the central neurones probably makes a significant contribution to the variability in the response to a given drug. Animal studies indicate that the affinities of receptors for particular agonists and antagonists are constant within and even between species (Rossum 1968 (Kutt et al. 1964 , Collste et al. 1972 , Smith 1969 , Schou et al. 1970 , Sjoqvist et al. 1971 ). Antipsychotic drugs have been studied little in this respect, partly because of methodological difficulties. However, monitoring the serum concentration would be particularly helpful in neuroleptic drug treatment since the clinical effect is often delayed and since embarrassing or even serious side-effects may occur.
At Department III of Lillhagen Hospital in Gothenburg, we developed a specific and highly sensitive method for determining haloperidol in serum and various tissues. It is based on gas chromatography, using an internal standard procedure. The results of some applications will be presented here together with data from studies on protein binding, metabolism and excretion. Methodological questions are not included in this account, since they were, or will be, presented elsewhere , 1975 After oral administration of haloperidol there was a time-lag of almost 1.5 hours between ingestion of the tablets and appearance of the drug in blood. The serum concentration increased to a maximum after four to six hours. The concentration curve then gradually turned into a slow exponential decay, similar to that after intravenous infusion. However, there was a second concentration peak after about 18 hours (i.e. when the individuals had lunch). Presumably this indicates excretion of the drug into the bile. The second peak would then result from reabsorption of the drug after emptying of the gall bladder. After oral administration of haloperidol, there was a gradual onset of sedation, lasting for several hours.
The bioavailability was calculated by comparing the surface under the concentration curve after intravenous and oral administration. It ranged from 44% to 74% with a mean value of 60% in the 6 patients studied in this respect. This means that only approximately 60o% of an oral dose of haloperidol finally reached the systemic circulation.
The serum half-life after intravenous infusion varied from 10.1 to 19 hours with a mean value of 15.6 hours. The estimated serum half-life was several hours longer after oral administration, indicating delayed absorption, or possibly enterohepatic recirculation of haloperidol. After determining C0, which would be the concentration at time zero if the distribution were instantaneous, the apparent volume of distribution could be calculated. When determined in this way it ranged from 1280 to 2130 litres.
The equation describing the serum concentration as a function of time was also calculated for each oral and intravenous experiment, using multiple regression analysis. This was performed using the BMDX 85 programme in an IBM computer. After testing various pharmacokinetic models, we found that an open three-compartment model, according to Gibaldi et al. (1971) 
Metabolism and Excretion ofHaloperidol
The metabolism of haloperidol in man has not previously been studied in detail. We isolated and identified a fluorobenzoyl carbonic acid and fluorophenyl uronic acid from human urine as metabolites of haloperidol. A pathway for the biodegradation of haloperidol in man could therefore be proposed , 1975 . As in the rat, the haloperidol molecule is split by oxidative dealkylation, resulting in hydrophilic fluorocarbonic acids, ultimately conjugated with glycine. Since the carbon-nitrogen bond is split, one does not expect the products to be psychopharmacologically active. Thus, the pharmacokinetics of the drug are equivalent to that of the one and only active substance.
Haloperidol is a lipid-soluble compound with a high protein binding. According to our studies only 1-4 % of haloperidol given orally, is excreted with urine. Conjugates of haloperidol have not been found in the urine. Biliary excretion (and reabsorption) might occur, at least after oral administration, as part of a first-pass effect.
These results cannot explain that more than one third of haloperidol elimination seems to be extrahepatic, according to the open threecompartment model described earlier. The suggestion that metabolism also takes place in extrahepatic organs would solve this problem.
Concluhding Remarks
Variability in clinical response to haloperidol is probably due to three main factors: the disease in question, variability in responsiveness of tissues and variability in pharmacokinetic parameters, influencing the concentration of the drug at its site of action. It seemed logical to start determining the extent of variability due to the third factor, pharmacokinetics.
Haloperidol is considered to be mainly a dopamine-receptor blocking agent, acting almost exclusively on the CNS. Until recently, studies on the pharmacokinetics and the metabolism of this drug were not possible because of methodological difficulties. The well-defined effects in the CNS; the absence of psychopharmacologically active metabolites and the small variation in the free fraction of haloperidol in serum should be helpful in the search for a correlation between haloperidol in serum (total concentration or free fraction) and clinical effects, provided that homogenous diagnostic groups are studied.
The one-to ten-fold variation in serum levels after comparable doses of haloperidol means that monitoring the drug concentration into a therapeutic range may be essential, particularly in long-term treatment of the chronically ill patient. Since the serum half-life was approximately 16 hours, administration twice daily is sufficient in most instances. According to our studies, extrapyramidal side-effects are not to be expected during the first 12 hours in previously untreated individuals. Blood pressure and pulse rate did not change significantly during the single dose experiments. Despite the absence of serious side-effects, the dose given to elderly patients should be reduced, since serum levels reached in this group are comparatively high.
Further studies on the pharmacokinetics of haloperidol may provide more detailed guidelines for the clinician to reduce therapeutic failure, as well as unnecessary side-effects. Such studies are presently carried out at Department I l[ of Lilihagen Hospital in Gothenburg. We are also looking beyond the concentration of drug aiid trying to determine the degree of receptor blockade in the central neurones. This may give an opportunity to quantify the influence of disease and of varying responsiveness of tissues on the total variability in clinical response to haloperidol. When trying to design the clinical profile of a drug, such variability should also be taken into account. DISCUSSION Dr G J Rockley (Manchester) said that phenothiazines in urine could be detected by relatively simple tests. He wondered whether thin-layer chromatography could be used in ordinary pathological practice. Such equipment was currently being used for the detection of amphetamines, for example.
Dr Forsman said that only 1-4% of the haloperidol molecule was found in the urine and that was easily detected by gas-liquid chromatography. The metabolites could be detected by thin-layer chromatography although the process was more complicated. The 
